Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by wofatson Sep 22, 2022 6:43pm
135 Views
Post# 34980438

RE:Revenue comparison 10 years later

RE:Revenue comparison 10 years laterThere is about 5 times as many shares of Knight so we are close to being halfway there I would think.
If revenue is 80+ for this quarter there is a good chance 300 is within grasp for this year.
Ebitda will start to be large enough so there maybe interest from others so some share price increase is visual .
As new drugs and territories are added into the mix now , price drops like this will be looked upon as opportunities for stock buybacks and adding to positions by investors .
Even with the stock being down we are seeing higher lows. 
It looks as though there is a base here. Still not a lot of volume.
Short positions have shrunk by almost a million shares since July 15.
This latest market downturn is a concern but all things end .

On the bright side we have the bashers to keep us amused while we wait.
I am looking forward to when a reasonable argument is going to be offered as to Why Not instead of Mugs is a Poo Poo (oops inside voice again)
 
<< Previous
Bullboard Posts
Next >>